Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Counseling | 10 | 2024 | 417 | 2.210 |
Why?
|
| Genetic Testing | 15 | 2024 | 1697 | 1.390 |
Why?
|
| Neoplastic Syndromes, Hereditary | 6 | 2024 | 232 | 1.320 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2024 | 5775 | 1.050 |
Why?
|
| Disclosure | 2 | 2018 | 180 | 1.020 |
Why?
|
| Counselors | 3 | 2024 | 27 | 0.830 |
Why?
|
| Genomics | 11 | 2024 | 2835 | 0.730 |
Why?
|
| Oncologists | 2 | 2023 | 136 | 0.730 |
Why?
|
| Germ-Line Mutation | 8 | 2024 | 1101 | 0.660 |
Why?
|
| Exome | 4 | 2024 | 1248 | 0.640 |
Why?
|
| Parents | 4 | 2024 | 1084 | 0.630 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 481 | 0.610 |
Why?
|
| Neoplasms | 11 | 2024 | 15909 | 0.570 |
Why?
|
| Whole Genome Sequencing | 2 | 2018 | 366 | 0.560 |
Why?
|
| Interviews as Topic | 2 | 2018 | 521 | 0.560 |
Why?
|
| Peutz-Jeghers Syndrome | 2 | 2017 | 59 | 0.550 |
Why?
|
| Haploinsufficiency | 2 | 2017 | 301 | 0.500 |
Why?
|
| Research Subjects | 1 | 2015 | 64 | 0.470 |
Why?
|
| Genetic Research | 1 | 2015 | 66 | 0.470 |
Why?
|
| Death | 1 | 2015 | 123 | 0.450 |
Why?
|
| Communication | 2 | 2018 | 835 | 0.440 |
Why?
|
| Health Personnel | 2 | 2018 | 649 | 0.430 |
Why?
|
| Li-Fraumeni Syndrome | 3 | 2022 | 166 | 0.420 |
Why?
|
| Professional-Family Relations | 3 | 2018 | 131 | 0.400 |
Why?
|
| Intestinal Polyposis | 2 | 2022 | 30 | 0.390 |
Why?
|
| Decision Making | 6 | 2024 | 1249 | 0.380 |
Why?
|
| Child | 22 | 2024 | 30517 | 0.380 |
Why?
|
| Genome, Human | 5 | 2022 | 1885 | 0.360 |
Why?
|
| Informed Consent | 3 | 2019 | 416 | 0.330 |
Why?
|
| Neuroblastoma | 2 | 2024 | 705 | 0.250 |
Why?
|
| Costello Syndrome | 1 | 2024 | 19 | 0.240 |
Why?
|
| Noonan Syndrome | 1 | 2024 | 29 | 0.240 |
Why?
|
| Phenotype | 4 | 2019 | 6504 | 0.240 |
Why?
|
| Humans | 40 | 2024 | 270631 | 0.230 |
Why?
|
| Information Seeking Behavior | 1 | 2023 | 20 | 0.220 |
Why?
|
| Neurofibromatosis 1 | 1 | 2024 | 159 | 0.210 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 283 | 0.210 |
Why?
|
| Health Literacy | 1 | 2024 | 117 | 0.210 |
Why?
|
| Family | 2 | 2024 | 784 | 0.210 |
Why?
|
| Adolescent | 11 | 2024 | 32719 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 2394 | 0.200 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 206 | 0.200 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 179 | 0.200 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 20 | 0.200 |
Why?
|
| Multilingualism | 2 | 2018 | 33 | 0.190 |
Why?
|
| MyoD Protein | 1 | 2021 | 33 | 0.190 |
Why?
|
| Brain Neoplasms | 3 | 2024 | 4957 | 0.180 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2020 | 71 | 0.180 |
Why?
|
| Ribonuclease III | 1 | 2022 | 182 | 0.180 |
Why?
|
| Adult | 11 | 2024 | 81946 | 0.180 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 256 | 0.170 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 58 | 0.170 |
Why?
|
| Child, Preschool | 8 | 2024 | 17028 | 0.170 |
Why?
|
| Smad4 Protein | 1 | 2020 | 201 | 0.170 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 117 | 0.170 |
Why?
|
| Medical Oncology | 2 | 2018 | 1463 | 0.160 |
Why?
|
| Patient Satisfaction | 1 | 2024 | 919 | 0.160 |
Why?
|
| Colectomy | 1 | 2020 | 292 | 0.160 |
Why?
|
| Watchful Waiting | 1 | 2020 | 293 | 0.150 |
Why?
|
| Counseling | 1 | 2020 | 381 | 0.150 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 74 | 0.150 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 341 | 0.150 |
Why?
|
| Cultural Competency | 1 | 2018 | 70 | 0.150 |
Why?
|
| Empathy | 1 | 2018 | 103 | 0.150 |
Why?
|
| Texas | 3 | 2024 | 6436 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 822 | 0.150 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2017 | 38 | 0.140 |
Why?
|
| Telemedicine | 1 | 2024 | 552 | 0.140 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2017 | 66 | 0.140 |
Why?
|
| Pinealoma | 1 | 2017 | 50 | 0.140 |
Why?
|
| Antigens, Nuclear | 1 | 2017 | 126 | 0.140 |
Why?
|
| Female | 16 | 2024 | 148865 | 0.140 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 734 | 0.130 |
Why?
|
| Patients | 1 | 2018 | 246 | 0.130 |
Why?
|
| Language | 1 | 2018 | 326 | 0.130 |
Why?
|
| Language Development Disorders | 1 | 2017 | 166 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2022 | 624 | 0.130 |
Why?
|
| Precision Medicine | 2 | 2021 | 1207 | 0.130 |
Why?
|
| Truth Disclosure | 1 | 2017 | 179 | 0.130 |
Why?
|
| Germ Cells | 3 | 2024 | 329 | 0.130 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2017 | 226 | 0.130 |
Why?
|
| Retinoblastoma | 1 | 2017 | 189 | 0.130 |
Why?
|
| Craniofacial Abnormalities | 1 | 2017 | 249 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 3707 | 0.130 |
Why?
|
| Male | 12 | 2024 | 128316 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2017 | 417 | 0.120 |
Why?
|
| Professional Role | 1 | 2015 | 76 | 0.120 |
Why?
|
| Microcephaly | 1 | 2017 | 333 | 0.120 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 916 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2019 | 572 | 0.110 |
Why?
|
| Young Adult | 6 | 2024 | 22201 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 1955 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 599 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3918 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 156 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 874 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 5001 | 0.100 |
Why?
|
| Polyps | 1 | 2012 | 81 | 0.100 |
Why?
|
| Infant | 4 | 2024 | 13982 | 0.100 |
Why?
|
| Heterozygote | 1 | 2014 | 1056 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 1503 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2017 | 1023 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2017 | 930 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2024 | 5439 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 852 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 1582 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2022 | 3656 | 0.090 |
Why?
|
| Stomach | 1 | 2012 | 402 | 0.080 |
Why?
|
| Middle Aged | 5 | 2024 | 90294 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2024 | 3152 | 0.080 |
Why?
|
| Translating | 2 | 2018 | 45 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 1049 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2573 | 0.070 |
Why?
|
| Homeodomain Proteins | 2 | 2024 | 1124 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 4790 | 0.060 |
Why?
|
| Population Groups | 1 | 2023 | 39 | 0.050 |
Why?
|
| Siblings | 1 | 2024 | 318 | 0.050 |
Why?
|
| Uncertainty | 1 | 2023 | 326 | 0.050 |
Why?
|
| Aged | 2 | 2024 | 73338 | 0.050 |
Why?
|
| ras Proteins | 1 | 2024 | 804 | 0.040 |
Why?
|
| Accreditation | 1 | 2020 | 136 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 175 | 0.040 |
Why?
|
| Mutation | 4 | 2022 | 15911 | 0.040 |
Why?
|
| Linguistics | 1 | 2018 | 26 | 0.040 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2018 | 17 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1655 | 0.040 |
Why?
|
| Patient Participation | 1 | 2023 | 453 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2018 | 52 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 403 | 0.040 |
Why?
|
| Pediatrics | 2 | 2017 | 1185 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 7263 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 657 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2020 | 522 | 0.030 |
Why?
|
| Larva | 1 | 2017 | 293 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 1231 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 2019 | 436 | 0.030 |
Why?
|
| Base Sequence | 1 | 2022 | 5437 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 2348 | 0.030 |
Why?
|
| Imidazoles | 1 | 2021 | 1064 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2017 | 295 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 229 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 457 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 478 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 965 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 362 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2017 | 402 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 2357 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 678 | 0.030 |
Why?
|
| United States | 2 | 2022 | 15834 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 349 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2024 | 7017 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 5914 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 854 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5464 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2014 | 635 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2357 | 0.020 |
Why?
|
| Health Behavior | 1 | 2014 | 600 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 5697 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 1339 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 2453 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 15204 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6766 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 7235 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 9471 | 0.020 |
Why?
|
| Animals | 2 | 2021 | 62031 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2024 | 39811 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 35586 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 14616 | 0.010 |
Why?
|